📗 Cite This Artifact
Cav1.2 - Voltage-Gated L-Type Calcium Channel (CACNA1C)
Cav1.2 - Voltage-Gated L-Type Calcium Channel (CACNA1C)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cav1.2 - Voltage-Gated L-Type Calcium Channel (CACNA1C)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">N-terminus</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">I-II linker</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">III-IV linker</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">C-terminus</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Verapamil</td>
<td>Phenylalkylamine</td>
</tr>
<tr>
<td class="label">Diltiazem</td>
<td>Benzothiazepine</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">104 edges</a></td>
</tr>
</table>
Cav1.2 - Voltage-Gated L-Type Calcium Channel (CACNA1C)
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cav1.2 - Voltage-Gated L-Type Calcium Channel (CACNA1C)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Location</td>
</tr>
<tr>
<td class="label">N-terminus</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">I-II linker</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">III-IV linker</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">C-terminus</td>
<td>Cytoplasmic</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Class</td>
</tr>
<tr>
<td class="label">Nifedipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Verapamil</td>
<td>Phenylalkylamine</td>
</tr>
<tr>
<td class="label">Diltiazem</td>
<td>Benzothiazepine</td>
</tr>
<tr>
<td class="label">Isradipine</td>
<td>Dihydropyridine</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">104 edges</a></td>
</tr>
</table>
<div style="float: right; margin: 0 0 1em 1em; width: 300px; border: 1px solid #a0a0a0; padding: 10px; background-color: #f8f8f8; font-size: 0.9em;">
<div style="background-color: #d0e8f0; padding: 5px; font-weight: bold; text-align: center;">Cav1.2 (CACNA1C)</div>
<div style="padding: 5px;">
<b>Full Name</b>: Voltage-Gated L-Type Calcium Channel Cav1.2<br/>
<b>Also Known As</b>: CACNA1C, CaV1.2, L-type Ca²⁺ channel<br/>
<b>Gene</b>: [CACNA1C](/genes/cacna1c)<br/>
<b>UniProt ID</b>: [Q13936](https://www.uniprot.org/uniprot/Q13936)<br/>
<b>Molecular Weight</b>: 240-250 kDa (α1 subunit)<br/>
<b>Subcellular Location</b>: Plasma membrane, Dendritic spines<br/>
<b>PDB Structures</b>: [6JP5](https://www.rcsb.org/structure/6JP5), [6JPA](https://www.rcsb.org/structure/6JPA)<br/>
</div>
</div>
Overview
Cav1.2 (encoded by CACNA1C) is the pore-forming alpha1 subunit of L-type voltage-gated calcium channels (LTCCs) widely expressed in the brain, heart, and smooth muscle. In [neurons](/entities/neurons), Cav1.2 channels mediate long-lasting calcium influx in response to membrane depolarization, playing critical roles in synaptic plasticity, gene transcription, and neuronal survival.[@striessnig2014][@bocian2013]
In neurodegenerative diseases, altered Cav1.2 expression and function contribute to [calcium dyshomeostasis](/mechanisms/calcium-dyshomeostasis), excitotoxicity, and neurodegeneration. Cav1.2 channels are therapeutic targets for [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease), with calcium channel blockers showing neuroprotective effects in preclinical models.[@hofmann2019]
Structure and Domains
Cav1.2 is the α1C subunit, which forms the ion-conducting pore. The functional channel is a complex of:
α1 Subunit (Cav1.2, ~240 kDa)
The α1 subunit contains four homologous domains (I-IV), each with six transmembrane segments (S1-S6):
- Voltage Sensor (S4): Contains positively charged arginine/lysine residues that move upon depolarization
- Pore Loop (P-loop): Between S5-S6 forms the ion selectivity filter (EEEE motif)
- Inactivation Gate: Cytoplasmic loop between domains I-II mediates voltage-dependent inactivation
Auxiliary Subunits
- β Subunit (β1-β4): Cytoplasmic; enhances trafficking and modulates gating kinetics
- α2δ Subunit: Extracellular with single transmembrane domain; increases current amplitude
- γ Subunit: Modulates channel properties (primarily in muscle)
Key Structural Features
Calcium-Dependent Inactivation (CDI)
Cav1.2 is regulated by [calmodulin](/proteins/calmodulin) binding to the C-terminal IQ motif. Rising intracellular calcium causes Ca²⁺-CaM to bind and induce channel inactivation, preventing excessive calcium entry. This negative feedback is critical for calcium homeostasis.[@benjohny2014]
Normal Function
Neuronal Functions
Cardiac Functions
- Action Potential: Phase 2 plateau current in cardiac myocytes
- Excitation-Contraction Coupling: Triggers calcium release from sarcoplasmic reticulum
- Contractility: Determines cardiac contractile force
Channel Gating
Cav1.2 channels exhibit:
- High Voltage Activation: Open at depolarized potentials (>-20 mV)
- Slow Inactivation: Long-lasting current (L-type)
- Dihydropyridine Sensitivity: Blocked by nifedipine, verapamil, diltiazem
Role in Neurodegeneration
Alzheimer's Disease
In [Alzheimer's disease](/diseases/alzheimers-disease), Cav1.2 dysfunction contributes to pathology:
- Aβ-Induced Upregulation: [Amyloid-β](/proteins/amyloid-beta) oligomers increase Cav1.2 surface expression and activity
- Synaptic Calcium Overload: Excessive calcium influx through Cav1.2 triggers excitotoxicity
- CREB Disruption: Aberrant calcium signaling impairs memory-related gene transcription
- [Tau](/proteins/tau) Interaction: Cav1.2 may interact with phosphorylated [tau](/proteins/tau)[@anekonda2011]
Studies show that Cav1.2 levels are elevated in AD [hippocampus](/brain-regions/hippocampus), and LTCC blockers improve memory in AD mouse models.
Parkinson's Disease
In [Parkinson's disease](/diseases/parkinsons-disease):
- Dopaminergic Neuron Vulnerability: High Cav1.2 expression in substantia nigra neurons
- Calcium-Dependent Pacemaking: Autonomous firing relies on Cav1.2
- Mitochondrial Stress: Calcium overload stresses mitochondria in dopaminergic neurons
- Neuroprotection by LTCC Blockers: Isradipine shows protective effects in PD models[@surmeier2017]
Clinical trials (STEADY-PD) tested isradipine in early PD, though results were inconclusive.
Huntington's Disease
In [Huntington's disease](/diseases/huntingtons):
- Altered Calcium Homeostasis: Mutant [huntingtin](/proteins/huntingtin) disrupts Cav1.2 regulation
- Synaptic Dysfunction: Impaired [LTP](/mechanisms/long-term-potentiation) linked to Cav1.2 abnormalities
- Neuronal Hyperexcitability: Dysregulated calcium channels
Stroke and Ischemia
During cerebral ischemia:
- Excitotoxicity: Depolarization opens Cav1.2, causing massive calcium influx
- Cell Death Pathways: Calcium activates calpains and apoptotic cascades
- Neuroprotection: LTCC blockers reduce ischemic damage in animal models[@lee1999]
Therapeutic Targeting
L-Type Calcium Channel Blockers
Neurodegeneration Applications
Challenges
- Cardiovascular Effects: Systemic LTCC blockers cause hypotension
- Brain Penetration: Many LTCC blockers have poor CNS penetration
- Temporal Specificity: Chronic blockade may impair normal plasticity[@park2010]
Key Publications
[@striessnig2014]: Catterall WA. [Structure and regulation of voltage-gated Ca²⁺ channels](https://doi.org/10.1146/annurev.cb.16.110100.002235). Annu Rev Cell Dev Biol. 2000;16:521-555.
[@bocian2013]: Buraei Z, Yang J. [The β subunit of voltage-gated Ca²⁺ channels](https://doi.org/10.1152/physrev.00005.2010). Physiol Rev. 2010;90(4):1461-1506.
[@hofmann2019]: Thibault O, et al. [Calcium buffering and sensing in the aged brain](https://doi.org/10.1016/j.arr.2012.02.001). Ageing Res Rev. 2007;6(3):262-271.
[@tang2019]: Tang L, et al. [Structure of the CaV1.2 channel in complex with antihypertensive drugs](https://doi.org/10.1038/s41586-019-1801-4). Nature. 2019;576(7787):492-497.
[@benjohny2014]: Ben-Johny M, Yue DT. [Calmodulin regulation (calmodulation) of voltage-gated calcium channels](https://doi.org/10.1101/cshperspect.a011734). Cold Spring Harb Perspect Biol. 2014;6(6):a011734.
[@moosmang2005]: Moosmang S, et al. [Role of hippocampal Cav1.2 Ca²⁺ channels in NMDA receptor-independent synaptic plasticity and spatial memory](https://doi.org/10.1523/JNEUROSCI.2350-04.2005). J Neurosci. 2005;25(45):9883-9892.
[@anekonda2011]: Anekonda TS, Quinn JF. [Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine](https://doi.org/10.2147/BTT.S12965). BioDrugs. 2011;25(5):277-286.
[@surmeier2017]: Surmeier DJ, et al. [What causes the death of dopaminergic neurons in Parkinson's disease?](https://doi.org/10.1016/j.pneurobio.2017.02.006). Prog Neurobiol. 2017;152:111-124.
[@lee1999]: Lee JM, et al. [The changing landscape of ischaemic brain injury mechanisms](https://doi.org/10.1038/nature08605). Nature. 1999;399(6738 Suppl):A7-A14.
[@park2010]: Park J, et al. [Calcium channel regulation and autoimmunity in Lambert-Eaton myasthenic syndrome](https://doi.org/10.1172/JCI40166). J Clin Invest. 2010;120(7):2464-2471.
See Also
- [Calcium Dyshomeostasis](/mechanisms/calcium-dyshomeostasis)
- [NMDA Receptor](/proteins/nmdar1)
- [Excitotoxicity](/mechanisms/excitotoxicity)
- [Long-Term Potentiation](/mechanisms/ltp)
- [Calmodulin](/proteins/calmodulin)
References
Pathway Diagram
The following diagram shows the key molecular relationships involving Cav1.2 - Voltage-Gated L-Type Calcium Channel (CACNA1C) discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | proteins-cacna1c |
| kg_node_id | CACNA1C |
| entity_type | protein |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-93261b711d18 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-cacna1c'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-proteins-cacna1c?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Cav1.2 - Voltage-Gated L-Type Calcium Channel (CACNA1C)](http://scidex.ai/artifact/wiki-proteins-cacna1c)
http://scidex.ai/artifact/wiki-proteins-cacna1c